ATRX loss is a useful biomarker in improving the diagnosis of IDH mutant astrocytomas and may be used to delineate these tumors from oligoastrocytomas and oligodendrogliomas [113,114]. This evidence concerns the gene ATRX and astrocytoma (excluding glioblastoma).